Alterity Therapeutics (ATHE) Non-Current Receivables (2015 - 2025)

Alterity Therapeutics has reported Non-Current Receivables for 11 years, with the latest figure at $4.5 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Receivables rose 20.86% year-over-year to $4.5 million; the trailing twelve-month figure through Dec 2025 stood at $4.5 million (up 20.86% YoY), and the FY2025 full-year result was $2.5 million, down 5.32% from the prior year.
• Non-Current Receivables for Q4 2025 stood at $4.5 million, up from $2.5 million in the prior quarter.
• The five-year high for Non-Current Receivables was $4.6 million in Q4 2022, with the low at $40416.8 in Q2 2024.
• Average Non-Current Receivables over 5 years is $3.1 million, with a median of $3.6 million recorded in 2022.
• Year-over-year, Non-Current Receivables surged 8095.97% in 2021 and slumped 97.44% in 2023.
• Tracing ATHE's Non-Current Receivables over 5 years: stood at $4.6 million in 2021, then climbed by 1.95% to $4.6 million in 2022, then fell by 16.22% to $3.9 million in 2023, then decreased by 4.58% to $3.7 million in 2024, then advanced by 20.86% to $4.5 million in 2025.
• The last three Non-Current Receivables figures came in at $4.5 million (Q4 2025), $2.5 million (Q2 2025), and $3.7 million (Q4 2024), per Business Quant data.

Peer Comparison